Table 2. Clinical Course Through 10 Weeks.
| No. | Age | Sex | Disease duration (years) | Disease location | Pretreated |
At baseline |
Treated |
At 10 weeks |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Previous treatment | PSL (mg) | Full Mayo | Endo scores | CRP (mg/dL) | TOF | Intensive GMA | Full Mayo | Endo scores | CR | CRP (mg/dL) | PSL (mg) | |||||
| 1 | 70 | M | 10 | Left-sided | IFX | 40 | 12 | 3 | 3.56 | + | + | 0 | 0 | + | 0.04 | 0 |
| 2 | 40 | M | 4 | Extensive | ADA | 40 | 10 | 2 | 0.99 | + | + | 1 | 1 | + | 0.04 | 0 |
| 3 | 45 | F | 29 | Left-sided | IFX | 0 | 6 | 3 | 0.03 | + | + | 3 | 1 | - | 0.03 | 0 |
| 4 | 58 | F | 22 | Extensive | 3 | 7 | 2 | 0.04 | + | + | 3 | 0 | - | 0.03 | 0 | |
| 5 | 64 | F | 32 | Left-sided | 5 | 9 | 3 | 0.16 | + | + | 2 | 1 | + | 0.01 | 0 | |
| 6 | 50 | F | 6 | Left-sided | ADA, AZA | Bude 2 | 7 | 2 | 0.04 | + | + | 2 | 1 | + | 0.01 | 0 |
| 7 | 46 | F | 10 | Extensive | 20 | 10 | 2 | 0.2 | + | + | 0 | 0 | + | 0.01 | 0 | |
PSL: prednisolone; Bude: budesonide; CRP: C-reactive protein; ADA: adalimumab; IFX: infliximab; TOF: tofacitinib; GMA: granulocyte and monocyte adsorptive apheresis; CR: clinical remission; AZA: azathioprine.